Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth
Source: SeekingAlpha
2025-12-18 12:47:31 ET
Thesis
Kalaris Therapeutics, Inc. (KLRS) is set to raise $50 million in a private placement by selling about 4.2 million shares at $10 each. Now, these sales also come with pre-funded warrants for 800,000 shares. The proceeds are expected to close tomorrow, December 19th....
Read the full article on Seeking Alpha
For further details see:
Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth
Kalaris Therapeutics Inc.
NASDAQ: KLRS
KLRS Trading
0.0% G/L:
$9.81 Last:
14,581 Volume:
$9.65 Open:
KLRS Latest News
January 28, 2026 04:05:00 pm
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
December 17, 2025 05:59:02 pm
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
December 17, 2025 04:01:00 pm
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD
KLRS Stock Data
$187,398,228
4,677,475
1.26%
26
N/A
Biotechnology & Life Sciences
Healthcare
US
Berkeley Heights
